Expanded blood PD-1hi Tfh cells in seropositive clinically suspect arthralgia predict progression to rheumatoid arthritis.

OBJECTIVES

Individuals with clinically suspect arthralgia (CSA, EULAR definition) are at increased risk of developing rheumatoid arthritis (RA) and early therapeutic intervention may delay or prevent progression. However, improved identification of likely progressors is needed to avoid unnecessary treatment. CD4+CXCR5+PD-1hi follicular helper (Tfh) and CD4+CXCR5-PD-1hi peripheral helper (Tph) T cells are implicated in RA pathogenesis. Notably, Tfh associate with favourable responses to co-stimulation blockade. Profiling these subsets in CSA could enhance our understanding of the RA preclinical phase, help identify progressors and select targeted therapies. Our objective was to assess circulating Tfh (cTfh) and Tph (cTph) cell frequencies in CSA.

METHODS

In this prospective, non-interventional study, peripheral blood was collected at baseline from CSA patients and age- and gender-matched healthy controls (HC). PBMCs were isolated and analysed by flow cytometry. Patients were followed until RA onset or for up to 48 months.

RESULTS

Compared with HC, seropositive CSA (RF and/or ACPA+, n = 33), but not seronegative CSA patients (n = 37), demonstrated expanded frequencies of cTfh and cTph cells. Among seropositive CSA patients, those who progressed to RA had higher baseline cTfh and cTph frequencies than non-progressors. A cTfh frequency >0.66% predicted progression (sensitivity 72%, specificity 85%). At RA onset, seropositive progressors (n = 19) showed a further increase in cTph, but not cTfh, frequency.

CONCLUSION

Seropositive CSA patients display elevated baseline cTfh and cTph frequencies. Higher cTfh proportions associate with progression to RA. These findings support the use of cTfh and cTph profiling to stratify progression risk and guide early therapeutic decisions in at-risk individuals.